Isabelle Mahé/LinkedIn
Aug 1, 2025, 13:11
Isabelle Mahé Shares an Insight from APICAT Study: Use of Apixaban in Cancer Associated Thrombosis
Isabelle Mahé, University Professor, Hospital Practitioner in Internal Medicine, shared an insightful post on LinkedIn:
”APICAT Study : reduced dose of apixaban for extended treatment in patient with Cancer associated Thrombosis.
A practice changing study.”
Read the full article here.
Article: ”Apixaban for Cancer-Associated Venous Thromboembolism”
Authors: Zhuo Shao, Xinyu Zhai
Stay updated on the latest scientific advancements in the field of thrombosis with Hemostasis Today.
-
Dec 20, 2025, 18:30Kate Scrivener on Cochrane Review: 2025 Ends With a Big Milestone!
-
Dec 20, 2025, 18:15Shekher Bose on AstraZeneca’s Voluntary Withdrawal of Andexxa
-
Dec 20, 2025, 17:10Mina Adel Nagi on the Future of ESR Testing with HORIBA’s CoRA Technology
-
Dec 20, 2025, 16:50Geert Verheyden on Advancing Stroke Rehabilitation Through Collaboration and Innovation
-
Dec 20, 2025, 16:26Dirk Sibbing on Antithrombotic Drugs for ACS in Women
-
Dec 20, 2025, 16:13Akshat Jain Explains VWF/FVIII Prophylaxis in Children Under 6
-
Dec 20, 2025, 15:49Manuel Requena Shares The Results of the RESISTANT International Registry
-
Dec 20, 2025, 13:49Harshal Kale: Wishing Our Community a Bright Start to 2026
-
Dec 20, 2025, 12:23Healthcare is a Human Right: Strengthening Blood Donation in Armenia